| C. Jeffrey Dekker |
C. Jeffrey Dekker is currently the Chief Financial Officer, Secretary & Treasurer at ARCA biopharma, Inc. He previously worked as the Vice President & Controller at NxTrend Technology, Inc. from 1993 to 1999, and at Requisite Technology, Inc. from 1999 to 2004. From 2004 to 2006, he served as the Vice President & Controller at Webroot LLC. He was also the Vice President-Finance at GlobeImmune, Inc. from 2006 to 2021. Additionally, he worked as a Senior Accountant at KPMG Peat Marwick LLP from 1986 to 1989. Mr. Dekker obtained his undergraduate degree from Utah State University in 1986. |
| Thomas A. Keuer |
Thomas A. Keuer is currently the President & Chief Executive Officer at ARCA biopharma, Inc. He previously held the position of Vice President-Engineering at Baxter Healthcare Corp. and Baxter International, Inc. He also served as Vice President-Operations at Somatogen, Inc. and as Senior Vice President-Operations at Insmed, Inc. Additionally, he was the Executive Vice President-Pharmaceutical Operations at ARCA biopharma, Inc. Mr. Keuer graduated from Rice University with a graduate degree and from The University of Texas at Austin with an undergraduate degree. |
| Robert E. Conway |
Robert E. Conway is currently the Chairman at ARCA biopharma, Inc., the Chairman at Wall Family Enterprise, Inc., the Executive Chairman at ClinOne, Inc., a Director at Biotechnology Innovation Organization, an Independent Director at Alpine Immune Sciences, Inc., a Director at Signant Health, a Director at Buccaneer Holdco Ltd., a Director at eResearch Technology, Inc., and a SAB Healthcare at Genstar Capital Management LLC. He previously served as the Chief Executive Officer & Director at Array BioPharma, Inc., a Director at PRA Health Sciences, Inc., a Director at ERT Operating Co., a Director at Bracket, Inc., a Director at Advarra, Inc., a Director at PRA International LLC, an Independent Director at Nivalis Therapeutics, Inc., the Vice President & General Manager at Corning, Inc., the Chief Operating Officer & Executive Vice President at Hill Top Research, Inc., the Vice President at Corning International Corp., and the Vice President & General Manager at Corning-Hazleton, Inc. He holds an undergraduate degree from Marquette University and an MBA from the University of Cincinnati (Ohio). |
| Michael R. Bristow |
Founder of Gilead Colorado, Inc., ARCA biopharma, Inc., ARCA biopharma, Inc. and miRagen Therapeutics, Inc., Michael R. Bristow is an entrepreneur who is President, Chief Executive Officer & Director at ARCA biopharma, Inc. Dr. Bristow is also Professor at the University of Colorado Health Sciences Center.
In the past he was Chairman, Chief Science & Medical Officer at ARCA biopharma, Inc. and Chief Science & Medical Officer at Gilead Colorado, Inc.
Dr. Bristow received a doctorate and an undergraduate degree from the University of Illinois. |
| Jacob Haft Ma-Weaver |
Jacob Haft Ma-Weaver founded Cable Car Capital LLC in 2013, where he is working as Portfolio Manager from 2013. Mr. Ma-Weaver also currently works at ARCA biopharma, Inc., as Independent Director from 2022 and Funicular Fund (BVI) Ltd., as Director. Mr. Ma-Weaver also formerly worked at Dodge & Cox, as Equity Research Associate. Mr. Ma-Weaver received his undergraduate degree in 2009 and graduate degree in 2009 from The Trustees of Columbia University in The City of New York. |
| Raymond L. Woosley |
Raymond L. Woosley founded Critical Path Institute. Dr. Woosley is on the board of Critical Path Institute (former Chairman, President & Chief Executive Officer), ARCA biopharma, Inc., Arizona Center for Education & Research on Therapeutics and Crediblemeds Worldwide, Inc. and Professor at the University of Arizona College of Medicine and Professor-Emeritus at Arizona Health Sciences Center.
Dr. Woosley previously was Member of Vanderbilt University and Director-Cardiovascular Sciences Institute at Georgetown University School of Medicine.
Raymond L. Woosley received a doctorate from the University of Louisville and a doctorate from the University of Miami. |
| Daniel J. Mitchell |
Daniel J. Mitchell founded Capital Health Venture Partners and Sequel Venture Partners LLC. Mr. Mitchell holds the position of Partner at Sequel Venture Partners LLC which he founded. Mr. Mitchell is Manager of Sequel Venture Partners III LLC and on the board of 5 other companies.
In his past career Mr. Mitchell was General Partner of Capital Health Venture Partners, Member of Excel Medical Ventures LLC and Principal at First National Bank of Chicago (Illinois).
Daniel J. Mitchell received an undergraduate degree from the University of Illinois and an MBA from the University of California, Berkeley. |
| Anders D. Hove |
Presently, Anders D. Hove is Managing Partner at Amzak Capital Management LLC. He is also Manager at Acorn Bioventures LP and on the board of 5 other companies.
In the past Dr. Hove held the position of Chief Executive Officer at Bellevue Asset Management LLC, Fund Manager at BB Biotech AG, General Partner for Venrock Associates and Managing Member at VHCP Management LLC (a subsidiary of Venrock Associates), Principal at Ciba-Geigy AG and Asset Manager at BB Medtech AG.
He received a graduate degree from Technical University of Denmark, a doctorate from the University of Copenhagen and an MBA from INSEAD. |
| James Flynn |
James Flynn is the founder of Nerium Capital LLC, which was founded in 2021. He is currently the Managing Member & Portfolio Manager at Nerium Capital LLC. Mr. Flynn's current jobs include being an Independent Director at RiceBran Technologies since 2024, a Director at MEI Pharma, Inc. since 2023, an Independent Director at ARCA biopharma, Inc. since 2022, a Director at Axiom Healthcare Strategies LLC since 2022, and a Director at Synlogic, Inc. since 2024. Mr. Flynn's former job was as a Manager-Healthcare Portfolio at Amici Capital LLC from 2008 to 2017. He obtained his undergraduate degree from Massachusetts Institute of Technology. |
